Related Experiment Video
Updated: Jun 6, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)
Published on: April 19, 2013
Monocyte chemoattractant protein 1-2518 A/G polymorphism and susceptibility to type 2 diabetes in a Chinese
Yali Jing1, Dalong Zhu, Yan Bi
1Department of Endocrinology, Affiliated Drum Tower Hospital, Medical College of Nanjing University, Jiangsu Province, China.
Background:
Hyperglycemia could accelerate monocyte chemoattractant protein 1 (MCP-1) production in monocytes and vascular endothelial cells. Recently, a genetic polymorphism (-2518 A/G) located in MCP-1 gene promoter has been found that could influence the expression of MCP-1. A large cohort study of Caucasians reported that MCP-1 G-2518 gene variant was negatively correlated with the prevalence of insulin resistance and type 2 diabetes. However, it is unclear whether this polymorphism is associated with type 2 diabetes in Han Chinese.
Methods:
We conducted a population-based case-control study of 416 type 2 diabetes cases and 416 controls.
Results:
Compared with the wild genotype AA, MCP-1 G-2518 gene variant could significantly decrease the prevalence of type 2 diabetes in Han Chinese (adjusted OR=0.49, 95% CI 0.32-0.77, P<0.0001). The results of stratified analyses indicated that a decreased risk of type 2 diabetes related with variant genotypes was evident in younger participants (age ≤50) (adjusted OR=0.35, 95% CI 0.20-0.61, P<0.0001), and similar results were observed in males (adjusted OR=0.37, 95% CI 0.21-0.66, P=0.001) and urban participants (adjusted OR=0.35, 95% CI 0.21-0.58, P<0.0001). In addition, a statistically significant difference was observed between MCP-1-2518 A/G polymorphism and waist to hip ratio.
Conclusions:
Our present pilot study indicated that MCP-1 G-2518 gene variant could significantly decrease the risk of type 2 diabetes in a Chinese population.
Related Concept Videos
Type II Diabetes I: Introduction
Single Nucleotide Polymorphisms-SNPs
Diabetes Mellitus: Type 2 and Gestational
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Type II Diabetes II: Pathophysiology
Type I Diabetes I: Introduction
